Merck Showcases HIV Pipeline at AIDS 2026, But Core Challenges Remain

What happened

Merck announced it will present new data on daily, weekly, and monthly options across its HIV treatment and prevention pipeline at the AIDS 2026 conference. This presentation highlights the company's efforts to diversify beyond its key oncology and vaccine franchises. However, the core investment thesis remains centered on the Keytruda patent cliff and the prolonged Gardasil China shipment suspension. The HIV pipeline is early-stage and does not provide near-term revenue offset to the ~$2.5B 2026 headwind from generics and IRA pricing. Until Merck demonstrates that new launches and pipeline progress can materially close the post-2028 gap, the risk/reward is unattractive.

Implication

Investors should view the HIV pipeline as a long-term optionality rather than a near-term catalyst. The stock remains range-bound between $105 and $135 until the company provides concrete evidence that the $2.5B 2026 headwind is contained and that non-Keytruda revenue pillars are scaling. Without a clear path to restart Gardasil shipments to China, the vaccine franchise will continue to drag. The AIDS 2026 data may generate short-lived enthusiasm, but it does not change the fundamental thesis that Merck is a WAIT. Key catalysts to watch remain the Q2 2026 earnings update for headwind quantification and any Gardasil China restart signals.

Thesis delta

The news modestly improves the pipeline narrative but does not shift the fundamental thesis. The wait stance remains justified as the market still needs proof of post-Keytruda diversification and resolution of Gardasil-China uncertainty.